Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GT307
- Development stage
- Phase 1
- Lead developer
- Grit Biotechnology
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
GT307 is an autologous tumor-infiltrating lymphocyte (TIL) therapy under clinical investigation for the treatment of advanced solid tumors, including advanced colorectal adenocarcinoma and other malignant solid neoplasms. The therapy involves isolating TILs from a patient's own tumor tissue, expanding them ex vivo, and then reinfusing them into the patient. Upon administration back into the patient, these autologous TILs specifically recognize and kill the patient's tumor cells[4]. This approach leverages the natural ability of lymphocytes to target cancer cells and is being developed as a form of personalized immunotherapy[1][2][3][4][6].
- Other names
- Autologous Tumor-Infiltrating Lymphocyte (GT307)Autologous TILs GT307
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on GT307.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GT307.